Analysts at Stifel Nicolaus initiated coverage on Biotie Therapies Oyj (ADR) BITI with a Buy rating.
The target price for Biotie Therapies is set to $30.
Biotie Therapies' shares rose 4.02 percent to $19.13 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
